Xeris Biopharma Holdings (XERS) executive compensation, 2026 proxy

John Shannon, Chief Executive Officer, was paid $5M in 2025, up 32% from $3.8M the year before. The CEO-to-median-employee pay ratio was 22:1, on median employee pay of $232,022.

Filed
April 23, 2026
Annual meeting
June 4, 2026
Pay year
2025
Named executives
5
CEO total pay
$5M+32% vs prior year
CEO to median employee
22:1median $232,022
CEO pay in equity
73%$3.7M in awards
Prior say-on-pay support
89%of votes cast
CEO Total Compensation
$5,042,584For fiscal 2025
CEO Pay Ratio
21.73:1Versus median employee
Say-on-Pay Support
88.9%At prior annual meeting
Bonus Payout Percentage
105%Of target for CEO and NEOs

How Shannon was paid

$5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary15%Stock awards56%Option awards17%Non-equity incentive12%All other compensation0%

Named executive officers

ExecutiveTotal
John ShannonChief Executive Officer$5,042,584
Steven M. PieperChief Financial Officer$1,874,090
Kevin McCullochPresident and Chief Operating Officer$2,270,973
Beth P. HechtChief Legal Officer and Corporate Secretary$1,895,274
Anh T. NguyenChief Medical Officer$2,000,648

What changed and why

  • $5MCEO total compensation increased to $5,042,584 in fiscal 2025 from $3,827,109 in fiscal 2024.
  • 44%Total product revenue and total revenue both increased by approximately 44% during 2025.
  • 120%Strategic corporate objectives under the annual incentive plan were overachieved at 120% of target.
  • 105%The annual incentive payout for the CEO and other NEOs was determined to be 105% of target.
  • Company remained adjusted EBITDA positive in every quarter of the 2025 fiscal year.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.